10 Biggest Stock Price Target Changes for April 13
Needham & Company lowered the stock price target for PROS (NYSE:PRO) from $80 to $40. The brokerage gave the stock a Buy rating. PRO stock closed at $30.48 on April 13.
B. Riley lowered the stock price target for Preferred Bank (NASDAQ:PFBC) from $65 to $40. The brokerage gave the stock a Neutral rating. PFBC stock closed at $35.37 on April 13.
Needham & Company lowered the stock price target for Cornerstone OnDemand (NASDAQ:CSOD) from $70 to $45. The brokerage gave the stock a Buy rating. CSOD stock closed at $31.05 on April 13.
HC Wainwright lowered the stock price target for Urogen Pharma (NASDAQ:URGN) from $75 to $53. The brokerage gave the stock a Buy rating. URGN stock closed at $23.71 on April 13.
DA Davidson lowered the stock price target for Yelp (NYSE:YELP) from $48 to $26. The brokerage gave the stock a Buy rating. YELP stock closed at $19.14 on April 13.
Mizuho lowered the stock price target for Aerie Pharmaceuticals (NASDAQ:AERI) from $54 to $34. The brokerage gave the stock a Buy rating. AERI stock closed at $15.11 on April 13.
Keefe, Bruyette & Woods lowered the stock price target for Encore Capital Group (NASDAQ:ECPG) from $50 to $35. The brokerage gave the stock an Outperform rating. ECPG stock closed at $26.49 on April 13.
Robert W. Baird lowered the stock price target for Helios Technologies (NASDAQ:HLIO) from $49 to $35. The brokerage gave the stock a Neutral rating. HLIO stock closed at $29.77 on April 13.
B. Riley raised the stock price target for Rogers (NYSE:ROG) from $125 to $135. The brokerage gave the stock a Buy rating. ROG stock closed at $99.77 on April 13.
Morgan Stanley raised the stock price target for Asbury Automotive Group (NYSE:ABG) from $51 to $61. The brokerage gave the stock an Equal Weight rating. ABG stock closed at $57.04 on April 13.
In combination with docetaxel, the U.S. Food and Drug Administration (FDA) has approved Bayer’s Nubeqa for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC).Nubeqa (darolutamide) was previously approved for the treatment of non-metastatic castration-resistant prostate ... [Read]
The UK government just enacted a regulation that prevents late-night advertising of junk food. The National Health Service (NHS) has begun to crack down on the promotion of unhealthy foods in an effort to reduce ... [Read]
Last week, we profiled some of the biggest potential penny stock gainers for the month of May. While many of those picks have already taken off, there are still plenty of stocks left to discuss. ... [Read]
Major stock markets saw a sharp dip Wednesday after investors were handed a dose of reality on the COVID-19 pandemic, but there were still a handful of penny stock gainers that are worth watching this ... [Read]
TD Securities raised the stock price target for The Descartes Systems Group (OTC:KXSCF) from $130 to $165. The brokerage gave the stock a Buy rating. KXSCF stock closed at $105.31 on May 5. Morgan Stanley ... [Read]
Guggenheim lowered the stock price target for Madison Square Garden Sports (NASDAQ:MSGS) from $350 to $216. The brokerage gave the stock a Buy rating. MSGS stock closed at $166.62 on May 4. Roth Capital raised ... [Read]
Jefferies Financial Group raised the stock price target for Methanex (NASDAQ:MEOH) from $13 to $36. The brokerage upgraded the stock from a Hold rating to a Buy rating. MEOH stock closed at $15.88 on May ... [Read]
SunTrust Banks lowered the stock price target for Ryman Hospitality Properties (NYSE:RHP) from $82 to $26. The brokerage gave the stock a Hold rating. RHP stock closed at $37.78 on April 29. SunTrust Banks lowered ... [Read]
HC Wainwright raised the stock price target for Arcturus Therapeutics (NASDAQ:ARCT) from $26 to $62. The brokerage gave the stock a Buy rating. ARCT stock closed at $30.53 on April 28. Wells Fargo lowered the ... [Read]
Risks and Disclosure:
Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.
All statements and opinions expressed are the opinions of the author and not of Microsmallcap.com or its officers. The author is wholly responsible for the validity of all statements. Microsmallcap.com was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay Microsmallcap.com to publish or syndicate this article.
This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Microsmallcap.com's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. Microsmallcap.com does not render general or specific investment advice. Any information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Microsmallcap.com does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.
Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Please see our full disclaimer here for additional details before making any investment decisions.
